
Dr Zeyad Nassar
Research Fellow (B) (with PhD)
South Australian Immunogenomics Cancer Institute
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Zeyad Nassar is a NHMRC Early Career Fellow in the Adelaide Medical School at the University of Adelaide. He graduated with a BSc in Pharmacy from the University of Applied Sciences in Jordan in 2007, a MSc in Pharmacology from the University of Science Malaysia in 2011 and a PhD in Pharmacology from the University of Queensland in 2015. He enjoyed a stellar undergraduate career, graduating in the top 3 Bachelor of Pharmacy students from the University of Applied Sciences in Jordan and making the University and Dean’s Honours Lists 7 times. He also won the Best Thesis Award from the University of Science Malaysia for his Masters Thesis. He has been funded by scholarships and fellowships throughout all stages of his research career, since commencing his Masters in 2010 to his current NHMRC Early Career Fellowship (2018-21). Dr Nassar has published 45 articles and 1 book chapter to date, 13 as first author and 3 as senior author.
Dr Nassar's research interests include prostate cancer, lipid metabolism and drug discovery.
Over the past 10 years of my postgraduate degrees and postdoctoral training, I have developed diverse experiences in cancer research including developing novel angiogenesis modulators for colon and breast cancer, deciphering the role of lipid raft proteins in prostate cancer progression, investigating the potential interplay between opioid analgesia and breast tumor metastasis, inspecting the role of lipid raft proteins in glioblastoma in responding to interstitial fluid pressure and tumor invasiveness, and finally lipid biology and metabolism in prostate cancer.
Since 2016, I have developed a deep interest in elucidating lipid metabolism and membrane lipid roles in the regulation of processes linked to aggressive and treatment resistant prostate cancer behaviors and investigating their potential for therapeutic targeting. My ultimate goal is to perform research that impacts patients’ lives. I have been funded by scholarships and fellowships throughout all stages of my research career. During my MSc and PhD degrees, I built extensive basic science expertise and employed multiple preclinical models focused on drug discovery and development for cancer. My MSc degree demonstrated the antiangiogenic activities of natural/synthetic products in colon and breast cancers. This work led to 1 patent for the natural product koetjapic acid, and 2 clinical trials for the natural product Nuvastatic™ (NCT04552600, NCT04546607). My PhD at The University of Queensland (UQ) studied 2 transmembrane proteins that form a special type of lipid rafts called caveolae. This work resulted in 5 first-author articles in high quality journals (Nature Reviews Urology and International Review of Cell and Molecular Biology, Oncotarget).
To achieve my goal of running a more translational research program, I relocated in 2016 to the University of Adelaide to work in a highly translational research group experienced in patient-derived models, biobanking, “bench to bedside” research and clinical trials. In prostate cancer (PCa), fatty acid oxidation (FAO) plays a crucial role in fueling disease initiation and progression. My research activities have provided strong evidence that PCa cells exhibit increased FAO compared to non-malignant cells and showed that clinical PCa is amenable to FAO targeting. I provided the first clinically relevant evidence, using patient-derived prostate tumor explants, that targeting FAO in prostate cancer is efficacious. In addition, I showed that activated FAO pathways mediate drug resistance and demonstrated that targeting FAO sensitizes PCa to novel drug treatments. I identified DECR1, which catalyzes the rate-limiting step in an auxiliary pathway for poly unsaturated fatty acid β-oxidation, as a previously unrecognized androgen-repressed and anti-ferroptosis enzyme in PCa cells and found its expression to be correlated with disease progression. This work provided a novel opportunity to target a selective class of fatty acids (with likely less toxicity), rather than shutting down FAO of all classes. My current projects:
1) Develop selective inhibitors against DECR1, this will be the first-in-field specific inhibitor for PUFA oxidation.
2) Investigate the epigenetic role of FAO in modulating gene expression to support PCa progression and treatment resistance.
3) Repurpose clinically-approved FAO inhibitors for PCa treatment.
4) Decipher the role of mitochondria dynamic proteins in PCa progression, and investigate the potential of targeting.
-
Appointments
Date Position Institution name 2022 - 2022 Postdoctoral research fellow SAiGENCI – South Australian immunoGENomics Cancer Institute 2018 - 2021 NHMRC Early Career Fellow University of Adelaide, Adelaide 2016 - 2017 Postdoctoral research scientist University of Adelaide 2015 - 2015 Postdoctoral research fellow University of Queensland -
Education
Date Institution name Country Title 2012 - 2015 University of Queensland Australia PhD 2009 - 2011 Universiti Sains Malaysia Malaysia MSc 2003 - 2007 Applied Science Private University Jordan BSc Pharmacy -
Research Interests
-
Journals
Year Citation 2022 Raftopulos, N. L., Washaya, T. C., Niederprum, A., Egert, A., Hakeem-Sanni, M. F., Varney, B., . . . Hoy, A. J. (2022). Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. Cancer & Metabolism, 10(1), 1-15.
WoS6 Europe PMC52022 Scott, J. S., Nassar, Z. D., Swinnen, J. V., & Butler, L. M. (2022). Monounsaturated fatty acids: key regulators of cell viability and intracellular signalling in cancer.. Mol Cancer Res, 20(9), 1354-1364.
Scopus6 WoS1 Europe PMC12021 Hammad, H. M., Imraish, A., Al-Hussaini, M., Zihlif, M., Harb, A. A., Abu Thiab, T. M., . . . Afifi, F. U. (2021). Ethanol extract of achillea fragrantissima enhances angiogenesis through stimulation of VEGF production. Endocrine, Metabolic and Immune Disorders - Drug Targets, 21(11), 2035-2042.
Scopus12021 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993.
Scopus18 WoS17 Europe PMC192021 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718.
Scopus25 WoS26 Europe PMC162020 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2020). Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibition. Molecular cancer research : MCR, 18(10), 1500-1511.
Scopus6 WoS6 Europe PMC52020 Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., . . . Butler, L. M. (2020). Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife, 9, 1-34.
Scopus59 WoS56 Europe PMC392020 Wu, Y., Xie, J., Xin, J., Lenchine, R. V., Wang, X., Fang, M. D., . . . Proud, C. G. (2020). eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA. Biochemical Journal, 477(22), 4367-4381.
Scopus18 WoS20 Europe PMC142020 Mah, C. Y., Nassar, Z. D., Swinnen, J. V., & Butler, L. M. (2020). Lipogenic effects of androgen signaling in normal and malignant prostate. Asian Journal of Urology, 7(3), 258-270.
Scopus17 Europe PMC112020 Pu, W., Qiu, J., Nassar, Z. D., Shaw, P. N., McMahon, K. A., Ferguson, C., . . . Parat, M. O. (2020). A role for caveola-forming proteins caveolin-1 and CAVIN1 in the pro-invasive response of glioblastoma to osmotic and hydrostatic pressure. Journal of Cellular and Molecular Medicine, 24(6), 3724-3738.
Scopus6 WoS6 Europe PMC42020 Nassar, Z. D., & Parat, M. -O. (2020). Caveola-forming proteins and prostate cancer. Cancer and Metastasis Reviews, 39(2), 415-433.
Scopus4 WoS3 Europe PMC22019 Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2019). Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Molecular Cancer Research, 17(4), 949-962.
Scopus50 WoS50 Europe PMC372019 Pu, W., Nassar, Z. D., Khabbazi, S., Xie, N., McMahon, K. A., Parton, R. G., . . . Parat, M. O. (2019). Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1. Journal of Neuro-Oncology, 143(2), 207-220.
Scopus6 WoS7 Europe PMC52019 Dighe, S. N., De la Mora, E., Chan, S., Kantham, S., McColl, G., Miles, J. A., . . . Ross, B. P. (2019). Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model. Communications Chemistry, 2(1), 14 pages.
Scopus19 WoS202018 Armstrong, H., Gillis, J., Johnson, I., Nassar, Z., Moldovan, M., Levrier, C., . . . Butler, L. (2018). Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Scientific reports, 8(1), 2090-1-2090-14.
Scopus23 WoS24 Europe PMC172018 Nassar, Z., Aref, A., Miladinovic, D., Mah, C., Raj, G., Hoy, A., & Butler, L. (2018). Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU International, 121(Suppl. 3), 9-21.
Scopus46 WoS43 Europe PMC322018 Xie, N., Matigian, N., Vithanage, T., Gregory, K., Nassar, Z., Cabot, P., . . . Parat, M. (2018). Effect of perioperative opioids on cancer-relevant circulating parameters: Mu opioid receptor and toll-like receptor 4 activation potential, and proteolytic profile. Clinical Cancer Research, 24(10), 2319-2327.
Scopus19 WoS17 Europe PMC102018 A Ishaqat, A., Abu-Dahab, R., M Hammad, H., Al-Zihlif, M., F Abaza, I., & Fatma U Afifi, Z. D. N. (2018). Phytochemical Analysis and Evaluation of Anti-angiogenic and Antiproliferative Activities of the Leaves of Elaeagnus angustifolia L. Grown in Jordan. Natural Products Chemistry & Research, 06(03), 1-6.
2017 Xie, N., Gomes, F., Deora, V., Gregory, K., Vithanage, T., Nassar, Z., . . . Parat, M. (2017). Activation of μ-opioid receptor and Toll-like receptor 4 by plasma from morphine-treated mice. Brain, Behavior, and Immunity, 61, 244-258.
Scopus33 WoS32 Europe PMC202017 Habib-Martin, Z., Hammad, H., Afifi, F., Zihlif, M., Al-Ameer, H., Saleh, M., . . . Nassar, Z. (2017). In vitro and in vivo evaluation of the antiangiogenic activities of Trigonella foenum-graecum extracts. Asian Pacific Journal of Tropical Biomedicine, 7(8), 732-738.
Scopus6 WoS32017 Al-Aqtash, R., Zihlif, M., Hammad, H., Nassar, Z., Meliti, J., & Taha, M. (2017). Ligand-based computational modelling of platelet-derived growth factor beta receptor leading to new angiogenesis inhibitory leads. Computational Biology and Chemistry, 71, 170-179.
Scopus9 WoS7 Europe PMC42017 Xie, N., Khabbazi, S., Nassar, Z. D., Gregory, K., Vithanage, T., Anand-Apte, B., . . . Parat, M. O. (2017). Morphine alters the circulating proteolytic profile in mice: functional consequences on cellular migration and invasion. FASEB Journal, 31(12), 5208-5216.
Scopus14 WoS14 Europe PMC72016 Armstrong, H., Koay, Y., Irani, S., Das, R., Nassar, Z., The Australian Prostate Cancer BioResource., . . . Butler, L. (2016). A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumor cells without induction of a heat shock response. Prostate, 76(16), 1546-1559.
Scopus21 WoS22 Europe PMC132016 Khabbazi, S., Nassar, Z. D., Goumon, Y., & Parat, M. O. (2016). Morphine decreases the pro-angiogenic interaction between breast cancer cells and macrophages in vitro. Scientific Reports, 6(1), 31572-1-31572-10.
Scopus26 WoS23 Europe PMC122015 Moon, H., Ruelcke, J., Choi, E., Sharpe, L., Nassar, Z., Bielefeldt-Ohmann, H., . . . Hill, M. (2015). Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1. Oncotarget, 6(10), 7438-7453.
Scopus41 WoS37 Europe PMC272015 Nassar, Z., Hill, M., Parton, R., Francois, M., & Parat, M. (2015). Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis. Oncoscience, 2(7), 635-645.
Scopus20 Europe PMC132014 Jafari, S., Khadeer Ahamed, M., Iqbal, M., Al Suede, F., Khalid, S., Haque, R., . . . Abdul Majid, A. (2014). Increased aqueous solubility and proapoptotic activity of potassium koetjapate against human colorectal cancer cells. Journal of Pharmacy and Pharmacology, 66(10), 1394-1409.
Scopus25 WoS23 Europe PMC52014 Al-Suede, F., Khadeer Ahamed, M., Abdul Majid, A., Baharetha, H., Hassan, L., Kadir, M., . . . Abdul Majid, A. (2014). Optimization of cat's whiskers tea (orthosiphon stamineus) using supercritical carbon dioxide and selective chemotherapeutic potential against prostate cancer cells. Evidence-based Complementary and Alternative Medicine, 2014, 396016-1-396016-15.
Scopus29 WoS17 Europe PMC82014 Shafaei, A., Syima Muslim, N., Nassar, Z., Aisha, A., Abdul Majid, A., & Ismail, Z. (2014). Antiangiogenic effect of Ficus deltoidea jack standardised leaf extracts. Tropical Journal of Pharmaceutical Research, 13(5), 761-768.
Scopus13 WoS82014 Hassan, L., Khadeer Ahamed, M., Abdul Majid, A., Baharetha, H., Muslim, N., Nassar, Z., & Abdul Majid, A. (2014). Correlation of antiangiogenic, antioxidant and cytotoxic activities of some Sudanese medicinal plants with phenolic and flavonoid contents. BMC Complementary and Alternative Medicine, 14(1), 1-14.
Scopus55 WoS46 Europe PMC202013 Zihlif, M., Afifi, F., Abu-Dahab, R., Abdul Majid, A., Somrain, H., Saleh, M., . . . Naffa, R. (2013). The antiangiogenic activities of ethanolic crude extracts of four Salvia species. BMC Complementary and Alternative Medicine, 13(1), 358-1-358-10.
Scopus25 WoS21 Europe PMC132013 Baharetha, H., Nassar, Z., Aisha, A., Ahamed, M., Al-Suede, F., Kadir, M., . . . Majid, A. (2013). Proapoptotic and antimetastatic properties of supercritical CO<inf>2</inf> extract of Nigella sativa Linn. Against breast cancer cells. Journal of Medicinal Food, 16(12), 1121-1130.
Scopus27 WoS23 Europe PMC172013 Nassar, Z., Moon, H., Duong, T., Neo, L., Hill, M., Francois, M., . . . Parat, M. (2013). PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget, 4(10), 1844-1855.
Scopus39 WoS37 Europe PMC272013 Nassar, Z., Hill, M., Parton, R., & Parat, M. (2013). Caveola-forming proteins caveolin-1 and PTRF in prostate cancer. Nature Reviews Urology, 10(9), 529-536.
Scopus42 WoS40 Europe PMC312012 Muslim, N., Nassar, Z., Aisha, A., Shafaei, A., Idris, N., Majid, A., & Ismail, Z. (2012). Antiangiogenesis and antioxidant activity of ethanol extracts of Pithecellobium jiringa. BMC Complementary and Alternative Medicine, 12(1), 210.
Scopus29 WoS18 Europe PMC52012 Nassar, Z., Aisha, A., Al Suede, F., Majid, A., & Majid, A. (2012). In vitro antimetastatic activity of koetjapic acid against breast cancer cells. Biological and Pharmaceutical Bulletin, 35(4), 503-508.
Scopus11 WoS10 Europe PMC32012 Piaru, S., Mahmud, R., Abdul Majid, A., & Mahmoud Nassar, Z. (2012). Antioxidant and antiangiogenic activities of the essential oils of Myristica fragrans and Morinda citrifolia. Asian Pacific Journal of Tropical Medicine, 5(4), 294-298.
Scopus57 WoS46 Europe PMC172012 Nassar, Z., Aisha, A., Idris, N., Khadeer Ahamed, M., Ismail, Z., Abu-Salah, K., . . . Abdul Majid, A. (2012). Koetjapic acid, a natural triterpenoid, induces apoptosis in colon cancer cells. Oncology Reports, 27(3), 727-733.
Scopus20 WoS17 Europe PMC92012 Ahamed, M., Aisha, A., Nassar, Z., Siddiqui, J., Ismail, Z., Omari, S., . . . Majid, A. (2012). Cat's whiskers tea (orthosiphon stamineus) extract inhibits growth of colon tumor in nude mice and angiogenesis in endothelial cells via suppressing VEGFR phosphorylation. Nutrition and Cancer, 64(1), 89-99.
Scopus49 WoS43 Europe PMC262011 Aisha, A. F., Nassar, Z. D., Siddiqui, M. J., Abu-Salah, K. M., Alrokayan, S. A., Ismail, Z., & Abdul Maji, A. M. S. (2011). Evaluation of Antiangiogenic, Cytotoxic and Antioxidant Effects of Syzygium aromaticum L. Extracts. Asian Journal of Biological Sciences, 4(3), 282-290.
2011 Nassar, Z., Aisha, A., Ahamed, M., Ismail, Z., Abu-Salah, K., Alrokayan, S., & Abdul Majid, A. (2011). Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr. Cancer Cell International, 11(1), 12.
Scopus23 WoS21 Europe PMC132011 Aisha, A., Abu-Salah, K., Nassar, Z., Siddiqui, M., Ismail, Z., & Majid, A. (2011). Antitumorigenicity of xanthones-rich extract from garcinia mangostana fruit rinds on HCT 116 human colorectal carcinoma cells. Brazilian Journal of Pharmacognosy, 21(6), 1025-1034.
Scopus9 WoS82010 Nassar, Z. D., Aisha, A. F. A., Majid, A. M. S. A., Yeap, C. S., & Fun, H. K. (2010). Koetjapic acid chloroform hemisolvate. Acta Crystallographica Section E: Structure Reports Online, 66(6), O1301-U491.
Scopus6 WoS4 Europe PMC22010 Muslim, N. S., Ng, K. W., Itam, A., Nassar, Z. D., Ismail, Z., & Abdul Majid, A. M. S. (2010). Evaluation of cytotoxic, anti-angiogenie and antioxidant properties of standardized extracts of Strobilanthes crispus leaves. International Journal of Pharmacology, 6(5), 591-599.
Scopus20 WoS13- HM, B., & ZD, N. (n.d.). Use of Nigella sativa Linn. Supercritical Carbon Dioxide Extract for Targeting the Angiogenesis Cascade. Medicinal & Aromatic Plants, 05(03).
- Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M. M., . . . Butler, L. M. (n.d.). DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
- Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (n.d.). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
- Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (n.d.). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S2 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S1 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Supplementary Figures and Legends 1-8 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (n.d.). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S2 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (n.d.). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Data from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (n.d.). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S1 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S3 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S3 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Data from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (n.d.). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S4 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Table S4 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (n.d.). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
- Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (n.d.). Supplementary Figures and Legends 1-8 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
- Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (n.d.). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
- Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (n.d.). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
- Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (n.d.). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
- Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (n.d.). Data from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.
- Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (n.d.). Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.
- Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (n.d.). Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.
-
Book Chapters
Year Citation 2016 Nassar, Z., & Parat, M. (2016). Cavin Family: New Players in the Biology of Caveolae. In Kwang Jeon (Ed.), International Review of Cell and Molecular Biology (Vol. 320, pp. 235-305). United Kingdom: Elsevier.
Scopus34 WoS36 Europe PMC22 -
Conference Papers
Year Citation 2017 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
-
Conference Items
Year Citation 2020 Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
WoS12020 Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
2020 Mah, C. Y., Nassar, Z. D., Burvenich, I. J., Irani, S., Centenera, M. M., Moldovan, M., . . . Butler, L. M. (2020). DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
2018 Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley. 2016 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley. -
Patents
Year Citation 2013 Nassar, Z., ABDUL MAJID, Amin Malik Shah., ABU-SALAH, Khalid M., ISMAIL, Zhari., AHAMED, Mohamed Khadeer., AISHA, Abdalrahim F.A., . . . ABDUL MAJID, Aman Shah. (2013). WO2013028051, Composition comprising Sandoricum koetjape extracts and uses thereof. PCT.
- The Hospital Research Foundation- Australia Prostate Cancer (2020)
- Cure Cancer Australia-Priority-driven Collaborative Cancer Research Scheme (2019).
- NHMRC Early Career Fellowship (2018-21)
- Prostate Cancer Foundation of Australia John Mills Young Investigator Award (2018-19)
- The University of Adelaide: Emerging Leadership Mentored Development Program (2018-19)
- Faculty of Health and Medical Sciences Research Infrastructure Funding Awards (2018)
- Freemasons Foundation Centre for Men's Health Postdoctoral Fellowship.
- Beat Project Travel Grant (2016).
- European Society for Medical Oncology (ESMO) Preceptorship Meeting Travel grant (2015).
- European Society for Medical Oncology (ESMO) translational research unit visit fellowship (2015).
- Cancer Council Queensland Travel Grant (2014).
- School of Pharmacy, University of Queensland, Travel Grant (2014).
- International Postgraduate Research Scholarship (IPRS) (2012-2015).
- University of Queensland Centenary Scholarship (2012-2015).
- University of Sciences Malaysia fellowship (2010-2011).
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Co-Supervisor Revealing the role metabolite solute carriers in AML stem cells Doctor of Philosophy Doctorate Full Time Ms Mahta Moraghebi 2021 Principal Supervisor The role of MFN2 in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Elizabeth Hannah Collis 2019 Co-Supervisor Androgen Regulation of Lipid Metabolism Doctor of Philosophy Doctorate Full Time Miss Julia Steele Scott -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2018 - 2021 Co-Supervisor Targeting fatty acid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Miss Chui Yan Mah -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2021 - ongoing External Supervisor DECR1 inhibition; a novel prostate cancer therapeutic target The University of South Australia - Doctorate Full Time James Paul Chakiris
Connect With Me
External Profiles